Actionable news
All posts from Actionable news
Actionable news in BLUE: bluebird bio, Inc.,

Bluebird Bio Selling 'An Overreaction,' Data Is 'Fantastic' Says Biotech Expert

View photo

Shares of bluebird bio Inc (NASDAQ: BLUE) were trading down more than 20 percent on Thursday morning.
  • The decline seems to have been triggered both by the company's earnings call and updated trial data for the treatment of beta-thalassemia.
  • Noted biotech analyst Jason Napodano weighed in on the issue.

Bluebird bio on Thursday announced that two beta0-beta0 genotypes beta-thalassemia patients needed blood transfusions, while one remains transfusion dependent. Reacting to the news (also to the company’s financial...